Leronlimab trial at MD Anderson Cancer Center

"Leronlimab is currently being trialed in combination with Keytruda (pembrolizumab) in a breast cancer xenograft model in partnership with MD Anderson Cancer Center."

https://www.biospace.com/article/embattled-cytodyn-sets-new-course-toward-nash-tough-tumors-/

"One of the most widely used models is the human tumor xenograft. In this model, human tumor cells are transplanted, either under the skin or into the organ type in which the tumor originated, into immunocompromised mice that do not reject human cells."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2562196/#:~:text=One%20of%20the%20most%20widely,do%20not%20reject%20human%20cells.

Here is a 2021 announcement of CytoDyn's trial:

https://www.biospace.com/article/releases/cytodyn-announces-study-to-evaluate-potential-synergistic-effects-of-leronlimab-with-immune-checkpoint-blockade-icb-/